Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. by Jiefeng Zhao (9090305)

Colocalization results. by Marie C. Sadler (9649799)

“…Mice experiments showed that dietary zinc deficiency decreased urinary but not plasma zinc levels, and upregulated kidney <i>Slc30a2</i> expression. …”

Finemapping results. by Marie C. Sadler (9649799)

“…Mice experiments showed that dietary zinc deficiency decreased urinary but not plasma zinc levels, and upregulated kidney <i>Slc30a2</i> expression. …”

Atg14 plays a cell-intrinsic role in orchestrating eTreg survival but not terminal differentiation. by Erienne G. Norton (9612079)

“…Pearson’s correlation (<b>A</b>), Benjamini–Hochberg test (<b>B</b>), two-tailed Student <i>t</i> test (<b>C</b>–<b>E, G</b>–<b>J</b>), or Fisher’s exact test (<b>F</b>); NS, not significant. …”

List of RT-qPCR primers. by Marie C. Sadler (9649799)

“…Mice experiments showed that dietary zinc deficiency decreased urinary but not plasma zinc levels, and upregulated kidney <i>Slc30a2</i> expression. …”

Image2_Asymmetric dimethylarginine induces maladaptive function of the blood-brain barrier.TIF by Tetyana P. Buzhdygan (19822401)

“…We found that ADMA disrupted physical barrier function as evident by significant decrease in electrical resistance and increase in paracellular permeability of hBMVEC monolayers. …”

Image1_Asymmetric dimethylarginine induces maladaptive function of the blood-brain barrier.TIF by Tetyana P. Buzhdygan (19822401)

“…We found that ADMA disrupted physical barrier function as evident by significant decrease in electrical resistance and increase in paracellular permeability of hBMVEC monolayers. …”

DataSheet1_RETRACTED: Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn.DOCX by Kislay Roy (3466256)

“…The blood analysis revealed a substantial decrease in the RBC, WBC, platelets, or the hemoglobin content post alkali burn. …”

Analysis of exophers and animal movement using logistic regression. by Rebecca J. Androwski (9444083)

“…On AD5, there is no difference between unmated and animals mated with sterile males while animals mated with fertile males results in a significant increase in exopher frequency. *** p < 0.001, “ns” = not significant by logistic regression, N = 50 per trial over two trials. …”

Effect of 1.25% of SCFP on MDR <i>Salmonella</i> serovars reduction at 24h. by Elena G. Olson (10649705)

Microbial differential abundance at 24 hours post-treatment was assessed using ANCOM (<i>P</i> <  0.05). by Elena G. Olson (10649705)

“…</i> Typhimurium DT104, and <i>S.</i> Reading. (a) The abundance of amplicon sequencing variants (ASVs) within <i>Enterobacterales</i> significantly decreased in the 1.25% SCFP treatment compared to the control at 24h, particularly in samples where <i>Salmonella</i> reduction was significant. …”

SD under different weights. by Jianrong Cai (14245136)

“…Case study results show a significant decrease in SD as the CAV penetration rate increases, with a 58.38% reduction from 0% to 100%. …”

Model framework. by Jianrong Cai (14245136)

“…Case study results show a significant decrease in SD as the CAV penetration rate increases, with a 58.38% reduction from 0% to 100%. …”

Vehicle travel time. by Jianrong Cai (14245136)

“…Case study results show a significant decrease in SD as the CAV penetration rate increases, with a 58.38% reduction from 0% to 100%. …”